Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Change in Receivables (2020 - 2025)

GeneDx Holdings has reported Change in Receivables over the past 6 years, most recently at $13.4 million for Q4 2025.

  • Quarterly results put Change in Receivables at $13.4 million for Q4 2025, up 2104.78% from a year ago — trailing twelve months through Dec 2025 was $36.2 million (up 599.44% YoY), and the annual figure for FY2025 was $36.2 million, up 599.44%.
  • Change in Receivables for Q4 2025 was $13.4 million at GeneDx Holdings, up from $12.9 million in the prior quarter.
  • Over the last five years, Change in Receivables for WGSWW hit a ceiling of $13.4 million in Q4 2025 and a floor of -$13.5 million in Q2 2022.
  • Median Change in Receivables over the past 5 years was -$243500.0 (2022), compared with a mean of $991150.0.
  • Peak annual rise in Change in Receivables hit 2359.42% in 2024, while the deepest fall reached 435.0% in 2024.
  • GeneDx Holdings' Change in Receivables stood at $5.3 million in 2021, then crashed by 100.69% to -$36000.0 in 2022, then soared by 655.56% to $200000.0 in 2023, then tumbled by 435.0% to -$670000.0 in 2024, then soared by 2104.78% to $13.4 million in 2025.
  • The last three reported values for Change in Receivables were $13.4 million (Q4 2025), $12.9 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.